keyword
MENU ▼
Read by QxMD icon Read
search

sacubitril

keyword
https://www.readbyqxmd.com/read/29239515/rationale-and-design-of-transition-a-randomized-trial-of-pre-discharge-vs-post-discharge-initiation-of-sacubitril-valsartan
#1
Domingo Pascual-Figal, Rolf Wachter, Michele Senni, Jan Belohlavek, Adele Noè, David Carr, Dmytro Butylin
AIMS: The prognosis after hospitalization for acute decompensated heart failure (ADHF) remains poor, especially <30 days post-discharge. Evidence-based medications with prognostic impact administered at discharge improve survival and hospital readmission, but robust studies comparing pre-discharge with post-discharge initiation are rare. The PARADIGM-HF trial established sacubitril/valsartan as a new evidence-based therapy in patients with heart failure (HF) and reduced left ventricular ejection fraction (<40%) (rEF)...
December 14, 2017: ESC Heart Failure
https://www.readbyqxmd.com/read/29237097/sacubitril-valsartan-instead-of-renin-angiotensin-system-inhibition-alone-a-step-forward-in-resistant-hypertension
#2
Konstantinos Stavropoulos, Konstantinos P Imprialos, Michael Doumas
No abstract text is available yet for this article.
December 13, 2017: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/29232274/from-theory-to-practice-the-diuretic-potential-of-sacubitril-valsartan-a-tale-of-2-patients
#3
Sabrina M Hormann, Lindsay E Davis, Elizabeth K Pogge
BACKGROUND: Heart failure prevalence continues to rise in the United States causing significant morbidity and mortality and costing billions in healthcare expenditures. Consensus guidelines updated in 2016 recommend an angiotensin receptor-neprilysin inhibitor (ARNi) as a therapeutic option in lieu of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker for the management of stage C heart failure with reduced ejection fraction (HFrEF). For chronic HFrEF patients with New York Heart Association class II or III symptoms tolerating an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, a change in therapy to an ARNi is recommended to further reduce morbidity and mortality...
December 11, 2017: Journal of Cardiovascular Nursing
https://www.readbyqxmd.com/read/29193563/sacubitril-valsartan-reduces-serum-uric-acid-concentration-an-independent-predictor-of-adverse-outcomes-in-paradigm-hf
#4
Ulrik M Mogensen, Lars Køber, Pardeep S Jhund, Akshay S Desai, Michele Senni, Søren L Kristensen, Andrej Dukát, Chen-Huan Chen, Felix Ramires, Martin P Lefkowitz, Margaret F Prescott, Victor C Shi, Jean L Rouleau, Scott D Solomon, Karl Swedberg, Milton Packer, John J V McMurray
AIMS: Elevated serum uric acid concentration (SUA) has been associated with an increased risk of cardiovascular disease, but this may be due to unmeasured confounders. We examined the association between SUA and outcomes as well as the effect of sacubitril/valsartan on SUA in patients with heart failure with reduced ejection fraction (HFrEF) in PARADIGM-HF. METHODS AND RESULTS: The association between SUA and the primary composite outcome of cardiovascular death or heart failure (HF) hospitalization, its components, and all-cause mortality was examined using Cox regression analyses among 8213 patients using quintiles (Q1-Q5) of SUA adjusted for baseline prognostic variables including estimated glomerular filtration rate (eGFR), diuretic dose, and log N-terminal pro-brain natriuretic peptide...
November 30, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29192956/initial-clinical-experience-with-the-first-drug-sacubitril-valsartan-in-a-new-class-arnis-in-patients-with-heart-failure-with-reduced-left-ventricular-ejection-fraction-in-poland
#5
Marta Kałużna-Oleksy, Jolanta Kolasa, Jacek Migaj, Agnieszka Pawlak, Małgorzata Lelonek, Jadwiga Nessler, Ewa Straburzyńska-Migaj
Sacubitril/valsartan is the first drug from a new class of angiotensin receptor neprilisin inhibitors (ARNIs) recommended in the new European Society of Cardiology's guidelines instead of ACEIs, or ARBs (angiotensin receptor antagonists) used if ACEIs are not tolerated, for further reduction in the risk of hospitalisation or death in outpatients with HFrEF if symptoms continue despite optimal treatment with ACEIs/ARBs, betablockers and MRAs (mineralocorticoid antagonists). The aim of this paper is to present the initial experience with regard to the effectiveness, tolerance and safety of sacubitril/valsartan in the outpatient cardiology practice in Poland...
December 1, 2017: Kardiologia Polska
https://www.readbyqxmd.com/read/29185253/cost-effectiveness-of-sacubitril-valsartan-in-chronic-heart-failure-patients-with-reduced-ejection-fraction
#6
Zanfina Ademi, Alena M Pfeil, Elizabeth Hancock, David Trueman, Rola Haroun Haroun, Celine Deschaseaux, Matthias Schwenkglenks
AIMS: We aimed to assess the cost effectiveness of sacubitril/valsartan compared to angiotensin-converting enzyme inhibitors (ACEIs) for the treatment of individuals with chronic heart failure and reduced-ejection fraction (HFrEF) from the perspective of the Swiss health care system. METHODS: The cost-effectiveness analysis was implemented as a lifelong regression-based cohort model. We compared sacubitril/valsartan with enalapril in chronic heart failure patients with HFrEF and New York-Heart Association Functional Classification II-IV symptoms...
November 29, 2017: Swiss Medical Weekly
https://www.readbyqxmd.com/read/29180454/effect-of-sacubitril-valsartan-on-exercise-induced-lipid-metabolism-in-patients-with-obesity-and-hypertension
#7
Stefan Engeli, Rudi Stinkens, Tim Heise, Marcus May, Gijs H Goossens, Ellen E Blaak, Bas Havekes, Thomas Jax, Diego Albrecht, Parasar Pal, Uwe Tegtbur, Sven Haufe, Thomas H Langenickel, Jens Jordan
Sacubitril/valsartan (LCZ696), a novel angiotensin receptor-neprilysin inhibitor, was recently approved for the treatment of heart failure with reduced ejection fraction. Neprilysin degrades several peptides that modulate lipid metabolism, including natriuretic peptides. In this study, we investigated the effects of 8 weeks' treatment with sacubitril/valsartan on whole-body and adipose tissue lipolysis and lipid oxidation during defined physical exercise compared with the metabolically neutral comparator amlodipine...
November 27, 2017: Hypertension
https://www.readbyqxmd.com/read/29174284/early-benefits-of-sacubitril-valsartan-hype-or-hope
#8
EDITORIAL
Vicente Bertomeu-González, Alberto Cordero
No abstract text is available yet for this article.
November 21, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29164797/impact-of-systolic-blood-pressure-on-the-safety-and-tolerability-of-initiating-and-up-titrating-sacubitril-valsartan-in-patients-with-heart-failure-and-reduced-ejection-fraction-insights-from-the-titration-study
#9
Michele Senni, John J V McMurray, Rolf Wachter, Hugh F McIntyre, Inder S Anand, Vincenzo Duino, Arnab Sarkar, Victor Shi, Alan Charney
AIMS: The TITRATION trial investigated two strategies to initiate and up-titrate sacubitril/valsartan (LCZ696) to the same target dose, over a condensed (3-week) or conservative (6-week) period, in patients with heart failure with reduced ejection fraction (HFrEF) and systolic blood pressure (SBP) of ≥100 mmHg. This post hoc analysis examined the relationship between baseline SBP at screening and achievement of the target dose of sacubitril/valsartan of 97 mg/103 mg (also termed 'LCZ696 200 mg') twice per day during the study...
November 22, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/29161389/innovations-in-management-of-cardiac-disease-drugs-treatment-strategies-and-technology
#10
P Foëx
Within the last generation, the management of patients with heart disease has been transformed by advances in drug treatments, interventions and diagnostic technologies. The management of arterial hypertension saw beta-blockers demoted from first- to third-line treatment. Recent studies suggest that the goal of treatment may have to change to lower systolic blood pressures to prevent long-term organ damage. Today less than 15% of coronary revascularizations are surgical and more than 85% are done by interventional cardiologists inserting coronary stents...
December 1, 2017: British Journal of Anaesthesia
https://www.readbyqxmd.com/read/29153212/-new-treatments-for-heart-failure
#11
Clément Venner, Olivier Huttin, Christine Selton-Suty, Yves Juillière
New direct oral anticoagulants are recommended as first-line therapy in case of atrial fibrillation within a heart failure. In the absence of atrial fibrillation, the role for new direct oral anticoagulants would have to be confirmed in the next years. Sacubitril/valsartan, angiotansin II receptor neprilysin inhibitor, presents with an efficacy superior to that of angiotensin converting enzyme inhibitors. It is now recommended in the treatment of heart failure as a third-line therapy. Modalities of prescription are strict, and safety is good...
November 2017: Soins; la Revue de Référence Infirmière
https://www.readbyqxmd.com/read/29146274/effects-of-angiotensin-neprilysin-inhibition-as-compared-to-angiotensin-inhibition-on-ventricular-arrhythmias-in-reduced-ejection-fraction-patients-under-continuous-remote-monitoring-of-implantable-defibrillator-devices
#12
Carlos de Diego, Luis González-Torres, José María Núñez, Raúl Centurión Inda, David A Martin-Langerwerf, Antonio D Sangio, Piotr Chochowski, Pilar Casasnovas, Julio C Blazquéz, Jesús Almendral
BACKGROUND: Angiotensin-neprilysin inhibition as compared to angiotensin inhibition decreased sudden cardiac death in reduced ejection fraction heart failure (rEFHF). The precise mechanism remains unclear. OBJECTIVE: To explore the effect of angiotensin-neprilysin inhibition on ventricular arrhythmias as compared to angiotensin inhibition in rEFHF patients with an implantable cardiac defibrillator (ICD) and remote monitoring. METHODS: We prospectively included 120 patients with ICD and: 1) New York Heart Association functional class≥ II, 2) left ventricular ejection fraction (LVEF) ≤40%, 3) remote monitoring...
November 13, 2017: Heart Rhythm: the Official Journal of the Heart Rhythm Society
https://www.readbyqxmd.com/read/29137346/safety-of-the-neprilysin-renin-angiotensin-system-inhibitor-lcz696
#13
REVIEW
Bo Li, Yunhe Zhao, Bo Yin, Mengfei Helian, Xinmei Wang, Feng Chen, Hongxia Zhang, Hui Sun, Bin Meng, Fengshuang An
Objectives: The combined neprilysin/rennin-angiotensin system inhibitor sacubitril/valsartan (LCZ696) has shown its superiority over ACEI/ARB therapy. In view of the existing concern of its adverse effects, we aimed to provide evidence of the safety of the new drug. Results: A total of 6 randomized trials with 11,821 subjects were included in this analysis. No significant differences were found in any adverse effects between LCZ696 and ACEI/ARB or placebo groups...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29132491/sacubitril-valsartan-practice-changing-guideline-in-the-management-of-congestive-heart-failure
#14
Muhammad Arsalan Karim, Hafiz Umair Siddiqui, Saad Ullah, Noman Ahmad Jang Khan
No abstract text is available yet for this article.
November 2017: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
https://www.readbyqxmd.com/read/29131824/predictive-model-identifies-key-network-regulators-of-cardiomyocyte-mechano-signaling
#15
Philip M Tan, Kyle S Buchholz, Jeffrey H Omens, Andrew D McCulloch, Jeffrey J Saucerman
Mechanical strain is a potent stimulus for growth and remodeling in cells. Although many pathways have been implicated in stretch-induced remodeling, the control structures by which signals from distinct mechano-sensors are integrated to modulate hypertrophy and gene expression in cardiomyocytes remain unclear. Here, we constructed and validated a predictive computational model of the cardiac mechano-signaling network in order to elucidate the mechanisms underlying signal integration. The model identifies calcium, actin, Ras, Raf1, PI3K, and JAK as key regulators of cardiac mechano-signaling and characterizes crosstalk logic imparting differential control of transcription by AT1R, integrins, and calcium channels...
November 13, 2017: PLoS Computational Biology
https://www.readbyqxmd.com/read/29129252/design-for-the-sacubitril-valsartan-lcz696-compared-with-enalapril-study-of-pediatric-patients-with-heart-failure-due-to-systemic-left-ventricle-systolic-dysfunction-panorama-hf-study
#16
RANDOMIZED CONTROLLED TRIAL
Robert Shaddy, Charles Canter, Nancy Halnon, Lazaros Kochilas, Joseph Rossano, Damien Bonnet, Christopher Bush, Ziqiang Zhao, Paul Kantor, Michael Burch, Fabian Chen
BACKGROUND: Sacubitril/valsartan (LCZ696) is an angiotensin receptor neprilysin inhibitor approved for the treatment of adult heart failure (HF); however, the benefit of sacubitril/valsartan in pediatric HF patients is unknown. STUDY DESIGN: This global multi-center study will use an adaptive, seamless two-part design. Part 1 will assess the pharmacokinetics/pharmacodynamics of single ascending doses of sacubitril/valsartan in pediatric (1 month to <18 years) HF patients with systemic left ventricle and reduced left ventricular systolic function stratified into 3 age groups (Group 1: 6 to <18 years; Group 2: 1 to <6 years; Group 3: 1 month to <1 year)...
November 2017: American Heart Journal
https://www.readbyqxmd.com/read/29084021/what-will-be-the-impact-of-sacubitril-valsartan-in-clinical-practice
#17
Marco Metra
: The Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial has shown a reduction in the risk of death and heart failure hospitalizations with sacubitril/valsartan, compared with enalapril, in patients with heart failure and reduced ejection fraction. Guidelines now recommend the substitution of angiotensin-converting enzyme inhibitor or AT1 blockers with sacubitril/valsartan in the patients who remain symptomatic despite ongoing optimal treatment...
October 27, 2017: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/29075957/pharmacogenomics-of-the-natriuretic-peptide-system-in-heart-failure
#18
REVIEW
Ahmed Abuzaanona, David Lanfear
PURPOSE OF REVIEW: Heart failure (HF) continues to be a public health burden despite advances in therapy, and the natriuretic peptide (NP) system is clearly of critical importance in this setting, spawning valuable diagnostic and prognostic testing, such as B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), as well as current and future therapeutics, including recombinant natriuretic peptides (e.g., carperitide, nesiritide) and recently sacubitril, which inhibits the key clearance mechanism for NPs...
December 2017: Current Heart Failure Reports
https://www.readbyqxmd.com/read/29059286/advantages-of-sacubitril-valsartan-beyond-blood-pressure-control-in-arterial-hypertension
#19
Gema Ruiz-Hurtado, Luis M Ruilope
No abstract text is available yet for this article.
October 20, 2017: European Heart Journal
https://www.readbyqxmd.com/read/29042791/profile-of-sacubitril-valsartan-in-the-treatment-of-heart-failure-patient-selection-and-perspectives
#20
REVIEW
Srikanth Yandrapalli, Gabriela Andries, Medha Biswas, Sahil Khera
With an estimated prevalence of 5.8 million in the USA and over 23 million people worldwide, heart failure (HF) is growing in epidemic proportions. Despite the use of guideline-directed medical therapies such as angiotensin-converting enzyme inhibitors, beta-adrenergic blockers, angiotensin receptor blockers, and mineralocorticoid receptor antagonists for chronic systolic HF for almost two decades, HF remains a leading cause of morbidity, mortality, and health care expenditures. The Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor with Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial provided compelling evidence for the cardiovascular and mortality benefit of sacubitril/valsartan when compared to enalapril in patients with heart failure and reduced ejection fraction (HFrEF)...
2017: Vascular Health and Risk Management
keyword
keyword
71365
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"